Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) has been given a consensus broker rating score of 1.83 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company.

Brokerages have set a 12-month consensus target price of $27.33 for the company and are predicting that the company will post ($0.49) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zealand Pharma A/S – American Depositary Shares an industry rank of 179 out of 265 based on the ratings given to related companies.

A number of brokerages recently issued reports on ZEAL. Zacks Investment Research downgraded Zealand Pharma A/S – American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Goldman Sachs Group initiated coverage on Zealand Pharma A/S – American Depositary Shares in a research report on Wednesday, September 27th. They set a “buy” rating on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Zealand Pharma A/S – American Depositary Shares in a report on Monday, October 16th.

Shares of Zealand Pharma A/S – American Depositary Shares (ZEAL) traded down $0.78 during trading hours on Friday, reaching $15.05. The company had a trading volume of 28,591 shares, compared to its average volume of 11,962. Zealand Pharma A/S – American Depositary Shares has a 1-year low of $12.45 and a 1-year high of $20.37.

Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.13. analysts forecast that Zealand Pharma A/S – American Depositary Shares will post -1.46 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new stake in shares of Zealand Pharma A/S – American Depositary Shares in the 3rd quarter valued at $3,185,000. Jane Street Group LLC acquired a new stake in shares of Zealand Pharma A/S – American Depositary Shares in the 3rd quarter valued at $386,000. Finally, Royce & Associates LP acquired a new stake in shares of Zealand Pharma A/S – American Depositary Shares in the 3rd quarter valued at $1,152,000. 13.33% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Zacks: Zealand Pharma A/S – American Depositary Shares (ZEAL) Given $27.33 Average Target Price by Brokerages” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/20/zacks-zealand-pharma-a-s-american-depositary-shares-zeal-given-27-33-average-target-price-by-brokerages.html.

About Zealand Pharma A/S – American Depositary Shares

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S – American Depositary Shares (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.